Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories

Simple item page
dc.contributor.authorLebogang, K
dc.contributor.authorOjo, BM
dc.contributor.authorOkubanjo, O
dc.contributor.authorSoremekun, R
dc.contributor.authorOluwole, A.
dc.date.accessioned2022-01-26T12:56:06Z
dc.date.available2022-01-26T12:56:06Z
dc.date.issued2020-04
dc.descriptionScholarly articlesen_US
dc.description.abstractThe development of novel paediatrics formulations is critical towards achieving the UNAIDS 90-90-90 targets. According to the latest UNAIDS reports, the availability of antiretrovirals (ARVs) for children has increased significantly, from 49% in 2015 to 53% in 2017. However, this percentage is considerably lower than the 80% for pregnant women that are currently on treatment. Therefore, there is still an urgent need for an alternative child-friendly delivery system. Lopinavir (LPV) is a protease inhibitor first-line HIV treatment drugs but suffers from low aqueous solubility, bitter state, short half-life leading to a limited dissolution and variable bioavailability upon oral administration. This work focused on the fabrication and characterization of a delivery system entailing Eudragit RSPO-LPV nanoparticles loaded suppositories in two different bases to improve the bioavailability and overcome the problem encountered through oral administration emanating from poor solubility. The prepared nanoparticles by nanoprecipitation method were characterized and compounded into suppositories in fattibase and polyethylene glycol (PEG) bases using a melt fusion method. The suppositories were stored at 5 and 25 °C, and were sampled at 0, 4, 8, 12 weeks. The samples were assessed by particle size, entrapment efficiency (EE), zeta potential and polydispersity index (PDI) variations. The preliminary in vitro release studies were analysed by HPLC. The nanoparticles have an average particle size of 191 nm with spherical morphology, entrapment efficiency, polydispersity index and zeta potential of 79.0 ± 0.5%, 0.224, and 25.87 ± 0.41 mV respectively. The surface analysis of the nanoparticles with FTIR, SEM, PXRD and TGA indicated that the drug w​a​s​ … Read moreen_US
dc.identifier.citationLebogang Katata-Seru, Ojo Babatunde Moses, Omotunde Okubanjo, Soremekun Rebcca, Oluwole Aremu. Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories Heliyon 6(5):e03890en_US
dc.identifier.issnDOI: 10.1016/j.heliyon.2020.e03890
dc.identifier.urihttps://ir.unilag.edu.ng/handle/123456789/10797
dc.language.isoenen_US
dc.subjectLopinaviren_US
dc.subjectNanoparticleen_US
dc.subjectHIV treatmenten_US
dc.subjectPediatricsen_US
dc.subjectResearch Subject Categories::PHARMACYen_US
dc.titleNanoformulated Eudragit lopinavir and preliminary release of its loaded suppositoriesen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
(7) (PDF) Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories.html
Size:
228.4 KB
Format:
Hypertext Markup Language
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Clinical Pharmacy and Biopharmacy- Scholarly Publications